BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation. Repurchases may be made from time to time through open market repurchases, privately negotiated transactions, or by other methods compliant with Rules 10b-18 and ...

Group 1 - BellRing Brands (BRBR) has been added to the Zacks Rank 5 (Strong Sell) List due to a downward revision of its current year earnings estimate by almost 14.6% over the last 60 days [1] - Azenta (AZTA) is also on the Zacks Rank 5 (Strong Sell) List, with its current year earnings estimate revised downward by 11.8% over the last 60 days [1] - Bridgestone (BRDCY) has seen its current year earnings estimate revised downward by almost 5.1% over the last 60 days, placing it in the automotive industry [2]

Core Insights - Diamond Hill Capital's "Large Cap Fund" underperformed the Russell 1000 Value Index in Q3 2025 despite a market rally, with the Russell 3000 Index gaining 8% and calendar-year returns exceeding 14% [1] Company Highlights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted in the investor letter, showing a one-month return of 6.16% and a 52-week gain of 2.11%, with a closing stock price of $567.64 and a market capitalization of $213.267 billion as of November 5, 2025 [2] - The company reported a revenue growth of 3% in Q2, reaching $10.85 billion, and is ranked 26th among the 30 Most Popular Stocks Among Hedge Funds, with 117 hedge fund portfolios holding its stock at the end of Q2 2025 [4] - Diamond Hill Capital initiated four new positions in Q3 2025, including Thermo Fisher Scientific Inc., indicating a belief that its stock price does not reflect its long-term growth potential [3]

Core Insights - Polen Capital's "Polen Focus Growth Strategy" reported a gross return of 3.34% and a net return of 3.14% for Q3 2025, underperforming the Russell 1000 Growth Index at 10.51% and the S&P 500 Index at 8.12% [1] - The equity market's strong performance was attributed to enthusiasm for generative AI and strength in the semiconductor sector, alongside positive economic surprises and better-than-expected corporate earnings [1] Company-Specific Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock, with a one-month return of 9.12% but a 52-week loss of 12.65%, closing at $524.58 per share with a market capitalization of $198.088 billion on October 13, 2025 [2] - Polen Focus Growth Strategy eliminated its position in Thermo Fisher Scientific to fund the purchase of Uber, citing ongoing macro, policy, and funding headwinds that are expected to persist [3] - Thermo Fisher Scientific's revenue grew 3% to $10.85 billion in Q2, and it ranked 26th among the 30 most popular stocks among hedge funds, with 117 hedge fund portfolios holding its stock at the end of Q2 [4]

Market Overview - The stock market experienced significant volatility in Q2 2025, with the S&P 500 reaching an all-time high by the end of June [1] - The market saw a drop of 7% from April 2 to April 7 due to the liberation day tariff announcement, followed by a rebound of over 22% from the April 7 low through the end of June [1] - The Russell 1000 Growth returned 17.8% and the S&P 500 returned 10.9% in the quarter, with large caps significantly outperforming small caps and growth outperforming value [1] Renaissance Large Cap Growth Strategy Performance - The strategy outperformed the S&P 500 Index but underperformed the Russell 1000 Growth benchmark [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as an underperformer, with a one-month return of -0.11% and a 52-week loss of 21.70% [2] - As of September 09, 2025, Thermo Fisher's stock closed at $487.65 per share, with a market capitalization of $182.859 billion [2] - The company reported solid operating results but saw a decline of 18.5% in its stock price, attributed to lowered full-year guidance due to tariff-related macro weakness and uncertainty regarding NIH funding delays impacting academic and government customers [3]

Core Viewpoint - Azenta, Inc. reported its financial results for the third quarter of fiscal 2025, showing a flat revenue year-over-year and a significant net loss due to discontinued operations and impairment charges. Financial Performance - Revenue from continuing operations was $144 million, unchanged from the previous year, with organic revenue declining by 2% year-over-year [3][8] - Sample Management Solutions revenue was $78 million, down 4% year-over-year, while Multiomics revenue increased to $66 million, up 4% year-over-year [3][8] - Diluted EPS from continuing operations was $0.01 compared to ($0.00) in the same quarter of the previous year, while total diluted EPS was ($1.15), a decrease of 30% from ($0.12) [3][8] - Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 12.3%, reflecting a 260 basis point improvement year-over-year [3][14] Management Commentary - The President and CEO, John Marotta, stated that significant organizational changes are underway, and the operational turnaround is progressing as planned, with a focus on cost management and execution [4][8] Cash and Liquidity - As of June 30, 2025, the company had a total balance of cash, cash equivalents, restricted cash, and marketable securities amounting to $565 million [14] - Operating cash flow for the quarter was $26 million, with capital expenditures of $11 million, resulting in free cash flow of $15 million [14] Guidance - Azenta reiterated its guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% relative to fiscal 2024 and an adjusted EBITDA margin expansion of approximately 300 basis points [14][8]

Company Overview - Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions globally, facilitating faster market access for impactful breakthroughs and therapies [3] - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, focusing on drug development, clinical research, and advanced cell therapies [3] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3] Upcoming Financial Announcement - Azenta will announce its fiscal third quarter 2025 earnings on August 5, 2025, before the market opens [1] - A conference call and live webcast to discuss the financial results will take place on the same day at 8:30 a.m. Eastern Time [2] - Analysts, investors, and media can access the live webcast through the Azenta website, with a replay available starting August 6, 2025, at 8:30 a.m. ET [2] Company Operations - Azenta is headquartered in Burlington, MA, and has operations across North America, Europe, and Asia [4]

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]

Company Overview - Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions globally, facilitating faster market access for impactful breakthroughs and therapies [3] - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, focusing on drug development, clinical research, and advanced cell therapies [3] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3] Financial Announcement - Azenta will announce its fiscal second quarter 2025 earnings on May 7, 2025, before the market opens, covering the period that ended on March 31, 2025 [1] - A conference call and live webcast to discuss the financial results will take place on the same day at 8:30 a.m. Eastern Time, accessible via the Azenta website [2] - A replay of the conference call will be available starting at 8:30 a.m. ET on May 8, 2025 [2] Operational Footprint - Azenta is headquartered in Burlington, Massachusetts, with operational presence in North America, Europe, and Asia [4]